Pliant Therapeutics, Inc. (PLRX)
After hours:
| Previous close | 15.61 |
| Open | 15.65 |
| Bid | 15.25 x 400 |
| Ask | 15.32 x 100 |
| Day's range | 15.23 - 15.87 |
| 52-week range | 11.21 - 24.74 |
| Volume | |
| Avg. volume | 372,731 |
| Market cap | 921.175M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.86 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.08 |
GlobeNewswirePliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared to placebo Bexotegrast 160 mg was well tolerated over 12 weeks of treatment with no serious adverse events and no discontinuations SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PL
Simply Wall St.Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
Pliant Therapeutics ( NASDAQ:PLRX ) First Quarter 2024 Results Key Financial Results Net loss: US$47.0m (loss widened...
GlobeNewswirePliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024. Title: Oral alpha-v/beta-6 and alpha
